Artificial intelligence used to help researchers plan experiments and better predict outcomes
Pandemic winners BioNTech and Moderna face hurdles as they seek to bring their groundbreaking technology to oncology
The first in an FT series looking at the new energy behind the fight for cancer cures
Jab makers fall behind Moderna in post-pandemic market with disappointing results
Pfizer and BioNTech infringed pharmaceutical group’s mRNA patent, High Court in London rules
Fears of growing outbreak drive revival in vaccine group stocks which have been out of favour since pandemic ended
Decision is a boon for the mRNA-vaccine maker in its legal fight to recoup pandemic profits from rivals
Moderna alleges Pfizer and BioNTech infringed its patents in use of mRNA platform
German group slashes guidance by €1bn and reduces spending as it expects fewer first vaccine doses and lower boosting
Biotech group hit by lower demand, with majority of write-offs relating to raw materials bought during pandemic
Companies have yet to provide investors with convincing post-pandemic strategies
Pharmaceuticals producer in first court hearing on Monday
European health officials have advocated portfolio diversity to help fight different variants
Expected fall highlights challenges for pharmaceutical companies that experienced pandemic windfall
Covid vaccine maker looks to use machine learning to help discover new treatments
Covid-19 vaccine maker hails ‘huge’ investment aimed at recruiting 10,000 participants with NHS
Success in battle against Covid does not ensure success against tumours, but should narrow the odds
Fall from €3.2bn in the third quarter of 2021 to €1.8bn
Pharmaceutical companies hunt for new revenue streams as coronavirus becomes endemic
Chinese biotech’s research chief calls decision ‘unfortunate’ as zero-Covid policy strangles economy
Experts are concerned that the US isn’t doing enough to support the development of the next wave of vaccines and treatments that the world needs to fight the Covid-19 pandemic
FDA clears jabs despite lack of human trials in effort to curb winter wave of Covid infections
US biotech claims rival Covid vaccine makers infringed patents underpinning jabs developed to combat the pandemic
Vaccine targeting BA.4/BA.5 could become first shot to win green light without human trials
German biotech aims for ‘prolonged and broad protection’ as sales and earnings miss expectations
